From the FDA Drug Label
If pregnant or breast-feeding, ask a health professional before use. The FDA drug label does not answer the question.
From the Research
Claritin (loratadine) is generally considered safe during breastfeeding, with a relative infant dose below 5% and minimal central nervous system effects, as reported in a systematic review of antihistamine use during breastfeeding 1. The typical adult dose is 10 mg once daily. Loratadine is less likely to cause drowsiness in both the mother and infant compared to older antihistamines like diphenhydramine (Benadryl). Some key points to consider when taking Claritin while breastfeeding include:
- Taking the medication immediately after nursing or just before the baby's longest sleep period to minimize exposure
- Monitoring the baby for any unusual drowsiness, irritability, or decreased feeding
- Contacting the healthcare provider if any concerning symptoms are noticed
- Being aware that the knowledge gap on antihistamines and lactation is extensive, and further human studies are warranted to ensure optimal treatment of breastfeeding women with allergy 1 It's also important to note that loratadine has been evaluated in several large controlled comparative clinical studies, and it was found to be superior to placebo and as effective as other antihistamines in patients with allergic rhinitis and chronic urticaria 2. Additionally, loratadine is considered to have a low dose and the convenience of once-daily dosing, making it a preferable option for some patients 3. However, it's crucial to prioritize the most recent and highest quality study, which in this case is the systematic review of antihistamine use during breastfeeding 1.